Tianish Laboratories Private Limited
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Process for the preparation of sofosbuvir (US 10,344,009) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Premix of crystalline raltegravir potassium salt and a process for the preparation thereof (US 10,391,178) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Mar 29, 2027The maintenance fee for Process for the preparation of Roflumilast (US 9,145,365) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Pure intermediate (US 9,150,524) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 2 fees due Jun 22 to 29, 2027 · next Jun 22
- 1 fee due Sep 1, 2027The maintenance fee for Process for the preparation of intermediates of HMG-CoA reductase inhibitors (US 9,273,333) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
Recent changes
- 4 terms have ended since Aug 23, 2026
- Oct 11 US 11,466,031 Polymorphic Forms of Bictegravir and Its Sodium Salt · lapsed on the fee record
- Oct 7 US 8,853,421 Novel Crystalline Forms of Zofenopril Calcium · lapsed on the fee record
- Sep 30 US 8,846,916 Sitagliptin Synthesis · lapsed on the fee record
- Sep 23 US 8,841,467 Process for the Preparation of (3R, 3AS, 6AR)-HEXAHYDROFURO [2, 3- B] FURAN-3-OL · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,119,662 | Crystalline compounds In force · USPTO record | In force | USPTO record | |
| US 9,221,754 | Novel Crystalline Forms of Zofenopril Calcium In force · High confidence | In force | High confidence | |
| US 8,946,265 | Process for the Preparation of Lenalidomide In force · High confidence | In force | High confidence | |
| US 9,150,524 | Pure intermediate In force · USPTO record | In force | USPTO record | |
| US 9,145,365 | Process for the preparation of Roflumilast In force · USPTO record | In force | USPTO record | |
| US 9,273,333 | Process for the preparation of intermediates of HMG-CoA reductase inhibitors In force · USPTO record | In force | USPTO record | |
| US 9,216,990 | Crystalline Darunavir In force · USPTO record | In force | USPTO record | |
| US 10,100,075 | Process for the preparation of sofosbuvir In force · USPTO record | In force | USPTO record | |
| US 10,391,178 | Premix of crystalline raltegravir potassium salt and a process for the preparation thereof In force · USPTO record | In force | USPTO record | |
| US 10,344,009 | Process for the preparation of sofosbuvir In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 10: 15 patents in force now held by others · 10 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.